UPCOMING WEBINAR: Prescription Drug Affordability Boards 101
Join Aimed Alliance for a FREE webinar on March 18, 2024 at 11AM ET – 12:00PM ET. Ensuring prescription drug affordability…
Browsing: Drug Pricing
Study Finds 340B Hospitals Significantly Markup Infusion Drugs
A recent study published in the New England Journal of Medicine examined the pricing practices of hospitals participating in the…
Senators Seek Input on Draft 340B Reform Bill
The Senate 340B Working Group is soliciting additional stakeholder input on key longstanding issues surrounding the Medicare 340B program. The…
Senate Pushes for FTC Progress in PBM Investigation
Senate Commerce Committee leaders, Maria Cantwell and Chuck Grassley, along with 12 lawmakers, are requesting an update from the Federal…
“Plan E”: A Proposal for a Universal Benefit for Cell and Gene Therapies
Cell and gene therapies (CGTs) have provided new optimism for patients living with diseases previously considered untreatable. These groundbreaking treatments…
Aimed Alliance Release New Resources on PDABs
On January 22, 2024, Aimed Alliance published two new resources on prescription drug affordability boards (PDABs). These boards, established at…
FDA Authorizes Florida’s Drug Importation Program
On January 5, 2024, the U.S. Food and Drug Administration (FDA) approved Florida’s Agency for Health Care Administration drug importation…
CBO Responds to Calls from the House Budget Committee to Consider New Data on IRA Impact on Innovation
Responding to inquiries from the House Budget Committee, the Congressional Budget Office (CBO) has signaled its openness to examining new…
House Budget Committee Questions CBO’s Analysis of the IRA’s Impact on Drug Development
On November 20, 2023, the House Budget Committee addressed a letter to the Congressional Budget Office (CBO), expressing concerns and…
Aimed Alliance Comments on IRA Patient Listening Sessions
Recently, Aimed Alliance submitted a comment to the Centers for Medicaid and Medicare Services (CMS) on the Patient Listening Sessions…